Home | Contact Us | For Vendors & Suppliers | Sitemap 
 
  Mr. Philip Yeo
 
Mr. Philip Yeo is the Chairman of the Board of Directors for A-Bio Pharma Pte Ltd.  Mr Yeo is currently the Special Advisor for Economic Development (Prime Minister's Office) and Chairman of SPRING Singapore.  He was formerly the Chairman of the Agency for Science, Technology and Research (A*STAR), the Economic Development Board (EDB) and the National Computer Board (NCB).  Prior to these appointments, Mr Yeo served in the Ministry of Defence where he held several appointments including the appointment of Permanent Secretary for Defence for logistics, technology research & development and defence industries.   Mr. Yeo is the recipient of many national and international awards from industries, institutions and governments, and was conferred an honorary doctorate in Engineering from the University of Toronto and an honorary degree of Doctor of Medicine by the Karolinska Institute.  In addition, Mr. Yeo is a board member in many listed companies.
 
 

  Mr. Clateo Castellini
 
Mr. Clateo Castellini holds a BA in Economics from Bocconi University in Milano, Italy and completed the Advanced Management Program at the Harvard Business School. He started his career in Lepetit , an Italian Pharmaceutical company, which was later acquired by Dow Chemical. At Lepetit and Dow he worked on various assignments in Europe, South America and US.  In 1978 Mr. Castellini joined Becton, Dickinson & Company and served in various postings around the world and later was posted to the Corporate Headquarter in New Jersey. In 1994 he became Chairman, President and CEO of Becton, Dickinson & Company and retired in 2002.
 
 

  Ms. Chu Swee Yeok
 
Ms. Chu Swee Yeok is the Chief Executive Officer of EDB Investments (EDBI), the strategic investment arm of the Singapore Economic Development Board.  She has over 20 years of track record and experience in investments, strategic planning, technology and industry development.  Concurrently, Swee Yeok is also the Chief Executive Officer of Bio*One Capital Pte Ltd (Bio*One), a subsidiary of EDBI, which operates as a dedicated investment company responsible for investments in high-growth global biomedical companies.  Since her appointment as CEO in 2004, Swee Yeok successfully led the Bio*One team through many transformational and impactful biomedical investments in Singapore and globally.  In additional to serving on the boards of EDBI and Bio*One, Swee Yeok holds a number of board positions in portfolio companies including S*Bio Pte Ltd, MerLion Pharmaceuticals Pte Ltd and The Novartis Institute of Tropical Diseases (NITD) in Singpoare.
 
 

  Mr. John Nine
 
Mr. John Nine holds a BS degree in pharmacy and an honorary science doctorate of pharmacy from Purdue University.  He received an honorary science doctorate of pharmacy from Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University and an honorary doctorate of Humane Letters from Florida A & M University. Mr. Nine joined Schering-Plough in 1975 as vice president - pharmaceutical production.  He later served as president - Schering technical operations for Schering Laboratories.  He subsequently served as senior vice president - Group C, and as president of Schering-Plough K.K., Japan. He was a Corporate Vice President  and President of Technical Operations. He is currently on the Board of Yonkers Industries, Cary, N. C., Aptuit and A-Bio and a Board Advisor at The Chao Center for Pharmaceutical Manufacturing. Mr. Nine served as the acting CEO for A-Bio Pharma at its initiation phase.
 
 

  Professor Daniel Wang
 
Professor Daniel Wang holds BS and PhD degrees in Chemical Engineering and an MS degree in Biochemical Engineering. He is an Institute Professor of Chemical Engineering at the Massachusetts Institute of Technology and a Temasek Professor at the National University of Singapore.  For more than 20 years, Professor Wang has held various positions and chairmanships in a number of technology organizations in US, Switzerland, Israel, China and Hong Kong. He is noted for his research in the fields of biotechnology and bioengineering and has served on many editorial boards, having contributed over 200 articles in journals relating to biotechnology, bioengineering and chemical engineering and authored or co-authored a number of books. He is the recipient of many awards and holds an Honorary Doctorate in Engineering from Hong Kong University of Science and Technology.
 
 

  Professor Miranda Gek Sim Yap
 
Professor Miranda Gek Sim Yap received her PhD in Chemical Engineering from the University of Toronto, Canada. She is the Executive Director of the Bioprocessing Technology Institute (BTI) in Singapore and is concurrently the Executive Director of A*STAR Graduate Academy (A*GA). Her other accomplishments include the formation of two other organizations: the Centre for Natural Product Research - now called Merlion Pharmaceuticals Pte Ltd and the Biopharmaceutical Manufacturing Technology Centre - now known as A-Bio Pharma Pte Ltd. Professor Yap is actively involved in research, supervising PhD candidates in the area of Animal Cell Technology and in developing manpower for the biopharmaceutical industry in Singapore. In February 2006, Professor Yap was named as a Foreign Associate of the US National Academy of Engineering for her achievements in education, research and management in the field of mammalian cell culture.
 
 
 
Board of Directors